Effects of GLP-1 receptor agonists on copeptin in euvolemic participants
Primary result · CopeptinResult — go to the resultMedian within-subject difference −.7 pmol/LAuthors' conclusion
Our analysis provides evidence that the GLP-1-RA dulaglutide inhibits the vasopressin system and proposes physiological mechanisms that may explain the role of GLP-1 in sodium and water balance.
Study context
- Population
- Euvolemic participants: 34 patients with primary polydipsia and 20 healthy participants; median age 27 years, 63% female, median body mass index (BMI) 23 kg/m²crossover
- Participants
- 54 participants
- Comparison
- Dulaglutide vs placebo
- Primary endpoint
- Copeptin levels (within-subject difference dulaglutide vs placebo)
- Follow-up
- After 3-week treatment
Methodological detailsdouble-blind, placebo-controlled, cross-over
- Double-blind
- Placebo-controlled
- Cross-over
Primary result
Copeptin · 3 weeks
Median within-subject difference
−.7 pmol/L
P = 0.047
As reported in the abstract
Further findings
Correlation of copeptin changes with reductions in blood pressure, BMI or nausea incidence
- Treatment-induced copeptin changes not significantly correlated with GLP-1-mediated reductions in blood pressure, BMI or incidence of nausea
Original publication
Effects of GLP-1 receptor agonists on copeptin in euvolemic participants. Eur J Endocrinol. Published 12 January 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →